Safety Assessment for Adding Contrave (Naltrexone/Bupropion) to Complex Medication Regimens
Seizure‑Threshold Considerations
- The combination of bupropion (the active component of Contrave) with agents that lower seizure threshold—such as antipsychotics (e.g., cariprazine) and antiepileptic drugs (e.g., lamotrigine when used for seizure control)—creates an absolute contraindication because it markedly raises seizure risk. 1
- The maximum approved bupropion dose in Contrave (360 mg/day) must not be exceeded; higher doses increase seizure incidence to >0.1 % in patients already receiving multiple seizure‑lowering medications. 2
Stimulant Interaction and Cardiovascular Risk
- Co‑administration of bupropion with amphetamine‑type stimulants (e.g., a total daily dose of 50 mg Adderall) can precipitate serotonin‑syndrome–like reactions and synergistic elevations in norepinephrine, leading to hypertension and tachycardia. 1
- Blood pressure and heart rate must be controlled before initiating Contrave because both naltrexone and bupropion can raise these parameters; uncontrolled hypertension is an absolute contraindication. 2
Required Medication Adjustments Before Initiation
- If lamotrigine is prescribed for seizure control, Contrave must be avoided entirely because bupropion is contraindicated in patients with active seizure disorders. 1
- When lamotrigine is used for mood stabilization, the stimulant dose should be reduced (e.g., consolidate to a single extended‑release dose) and the necessity of cariprazine should be reassessed to lower cumulative seizure risk. 1
Contrave Titration Protocol (if all safety criteria are met)
- Week 1: 8 mg naltrexone / 90 mg bupropion once daily in the morning.
- Week 2: 8 mg / 90 mg twice daily (second dose taken before 3 PM to reduce insomnia).
- Week 3: 16 mg / 180 mg in the morning + 8 mg / 90 mg in the evening.
- Week 4 and beyond: 16 mg / 180 mg twice daily (total 32 mg / 360 mg per day).
- Exceeding the total daily dose of 32 mg naltrexone / 360 mg bupropion markedly increases seizure risk and must be avoided. 2
Monitoring During Initiation and Ongoing Therapy
- First 1–2 weeks (high‑risk period): Screen for suicidal ideation, agitation, irritability, and early signs of serotonin syndrome (confusion, tremor, clonus, hypertension, tachycardia, sweating). 1
- Seizure surveillance: Watch for aura, confusion, or muscle twitching as early warning signs. 3
- Blood pressure and heart rate: Perform baseline measurement and repeat at least weekly for the first 12 weeks; adjust antihypertensive therapy as needed. 2
- Efficacy checkpoint at 12 weeks: Discontinue Contrave if weight loss is <5 % of baseline body weight. 2
Medications With No Required Adjustment
- Buspirone (10 mg twice daily PRN) does not have a clinically significant interaction with Contrave. 1
- Eszopiclone (3 mg nightly) is compatible; bupropion’s activating effect may modestly improve sleep quality. 1
- Propranolol (10 mg daily) may be beneficial for counteracting Contrave‑induced cardiovascular effects, provided blood pressure is adequately controlled. 2
Critical Pitfalls to Avoid
- Do not exceed the approved maximum dose of Contrave (32 mg naltrexone / 360 mg bupropion daily). 2
- Do not skip intensive monitoring during weeks 1–2, as this period carries the highest risk for suicidal ideation and serotonin‑syndrome–like events. 1
- Do not continue Contrave beyond 12 weeks without confirming ≥5 % weight loss; otherwise discontinue therapy. 2
- Do not administer the second daily dose after 3 PM to minimize insomnia risk. 1
Alternative FDA‑Approved Weight‑Loss Options (when Contrave is unsafe)
| Medication | Typical Dose | Key Safety Profile |
|---|---|---|
| Liraglutide (Saxenda) | 3.0 mg subcutaneously daily | GLP‑1 receptor agonist; no seizure risk or stimulant interaction. |
| Orlistat (Xenical) | 120 mg orally three times daily with meals | No known drug‑drug interactions with the listed regimen; gastrointestinal side effects may limit adherence. |
- Phentermine/topiramate ER (Qsymia) is not recommended because topiramate can interact with lamotrigine and the stimulant component adds to sympathomimetic burden. 4